2.6588

0.00% 0.0012

Processa Pharmaceuticals Inc (PCSA)

Overview News Price History Financials Discussions Forecast Stock Split

Processa Pharmaceuticals Inc stock is traded at $2.6588, with a volume of 4,921. It is up +0.00% in the last 24 hours and down -5.00% over the past month. Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

Previous Close:

$2.66

Open:

$2.66

24h Volume:

4,921

Relative Volume:

0.09

Market Cap:

$7.22M

Revenue:

Net Income/Loss:

$-13.56M

P/E Ratio:

-0.2733

EPS:

-9.7281

Net Cash Flow:

$-12.24M

1W Performance:

+0.38%

1M Performance:

-5.00%

6M Performance:

-66.32%

1Y Performance:

-59.17%

1-Day Range:

$2.61

$2.68

1-Week Range:

$2.50

$2.89

52-Week Range:

$1.76

$19.63

Processa Pharmaceuticals Inc Stock (PCSA) Company Profile

Name

Processa Pharmaceuticals Inc

Sector

Healthcare (1107)

Industry

Biotechnology (615)

Phone

443-776-3133

Address

601 21ST STREET, SUITE 300, VERO BEACH

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

PCSA's Discussions on Twitter

Compare PCSA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCSA Processa Pharmaceuticals Inc	2.6349	7.29M	0	-13.56M	-12.24M	-9.7281
VRTX Vertex Pharmaceuticals Inc	428.25	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	720.03	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	811.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	304.18	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	315.00	33.06B	5.36B	287.73M	924.18M	2.5229

Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-25-24	Initiated	H.C. Wainwright	Buy

Processa Pharmaceuticals Inc Stock (PCSA) Latest News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
SKIBSTED RUSSELL	Chief Financial Officer	Apr 30 '26	Buy	2.69	2,190	5,891	6,498
Ng George K	Chief Executive Officer	Apr 30 '26	Buy	2.69	2,034	5,471	6,013
Lin Patrick	Chief Business - Strategy Off	Apr 30 '26	Buy	2.69	1,511	4,065	6,236
Guy Wendy	Chief Administrative Officer	Apr 30 '26	Buy	2.69	1,748	4,702	6,441
Bigora Sian	Chief Development Officer	Apr 30 '26	Buy	2.69	1,986	5,342	7,496
Young David	Pres. Research & Development	Apr 15 '26	Buy	2.97	1,545	4,589	12,107
Ng George K	Chief Executive Officer	Apr 15 '26	Buy	2.97	1,843	5,474	5,492
Lin Patrick	Chief Business - Strategy Off	Apr 15 '26	Buy	2.97	1,369	4,066	4,725
Guy Wendy	Chief Administrative Officer	Apr 15 '26	Buy	2.97	1,583	4,702	4,693
Bigora Sian	Chief Development Officer	Apr 15 '26	Buy	2.97	1,799	5,343	5,510

Processa Pharmaceuticals Inc (PCSA)

Processa Pharmaceuticals Inc Stock (PCSA) Company Profile

Compare PCSA vs VRTX, REGN, ARGX, ALNY, ONC

Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades

Processa Pharmaceuticals Inc Stock (PCSA) Latest News

Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ng George K - Moomoo

Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus

Processa Pharmaceuticals CFO Skibsted buys $5,891 in stock By Investing.com - Investing.com Australia

Processa Pharmaceuticals CFO Skibsted buys $5,891 in stock - Investing.com

Processa Pharma strategy chief Lin buys $4,064 in stock By Investing.com - Investing.com India

Processa Pharma strategy chief Lin buys $4,064 in stock - Investing.com

Processa (PCSA) CAO Wendy Guy buys 1,748 shares in open-market trade - Stock Titan

Processa Pharmaceuticals president David Young buys $4,589 in shares By Investing.com - Investing.com Australia

Processa Pharmaceuticals CEO George Ng buys $5,471 in company stock By Investing.com - Investing.com India

Processa Pharmaceuticals president David Young buys $4,589 in shares - Investing.com

Processa Pharmaceuticals CEO George Ng buys $5,471 in company stock - Investing.com

David Young of Processa (NASDAQ: PCSA) buys 1,706 shares at $2.69 - Stock Titan

Processa Pharmaceuticals (PCSA) CFO adds 2,190 shares in open-market buy - Stock Titan

Processa (NASDAQ: PCSA) CEO George Ng buys 2,034 shares in open-market trade - Stock Titan

Processa (PCSA) strategy chief buys 1,511 shares at $2.69 - Stock Titan

Processa (NASDAQ: PCSA) CDO adds 1,986 shares in open-market buy - Stock Titan

2025 Executive Compensation, Ownership, and Governance Overview for Heatwurx, Inc. (Now Based in Vero Beach, FL) - Minichart

Processa Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Ng George Kmoomoo - Moomoo

Processa Pharmaceuticals Announces Transition of Chief Development Officer - TipRanks

Processa Pharmaceuticals CEO George Ng buys $5,414 in stock By Investing.com - Investing.com Canada

Processa Pharmaceuticals (NASDAQ: PCSA) details governance, pay and ownership in 10-K/A - Stock Titan

Chief development leader at Processa (NASDAQ: PCSA) moves to part-time post - Stock Titan

Processa Pharmaceuticals CEO George Ng buys $5,414 in stock - Investing.com

Processa (NASDAQ: PCSA) CEO adds 1,843 shares in open-market buy - Stock Titan

Processa Pharmaceuticals (PCSA) CEO buys 2,136 shares in open market - Stock Titan

PCSA stock rallies 10% after hours—here’s why - MSN

Processa Pharmaceuticals Inc. (PCSA) Share Price Today | Processa Pharmaceuticals (PCSA) Live NSE/BSE - Value Research

PCSA Stock Price, Quote & Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill

Is Processa Pharmaceuticals (PCSA) stock testing important levels (Pressure Mounts) 2026-04-20Wall Street Picks - Xã Thanh Hà

Processa Pharma director Young buys shares worth $4,588 By Investing.com - Investing.com Australia

Lin Patrick, Processa Pharma chief, buys $4,065 in PCSA stock By Investing.com - Investing.com South Africa

Processa Pharma director Young buys shares worth $4,588 - Investing.com

Lin Patrick, Processa Pharma chief, buys $4,065 in PCSA stock - Investing.com

Bigora Sian, chief development officer, buys Processa shares By Investing.com - Investing.com Australia

Processa Pharma CFO Skibsted buys $5892 in PCSA stock By Investing.com - Investing.com Canada

Bigora Sian, chief development officer, buys Processa shares - Investing.com

Processa Pharmaceuticals (NASDAQ: PCSA) R&D chief buys 1,545 shares in open market - Stock Titan

Processa Pharmaceuticals (PCSA) CEO adds 1,843 shares in open-market buy - Stock Titan

Processa (PCSA) strategy chief buys 1,369 shares at $2.97 - Stock Titan

Processa (NASDAQ: PCSA) CAO Wendy Guy buys 1,583 shares in open market - Stock Titan

Processa (PCSA) CDO buys 1,799 company shares in open market - Stock Titan

Processa (NASDAQ: PCSA) CFO adds 1,984 shares in open-market buy - Stock Titan

Institution Moves: Is Processa Pharmaceuticals Inc impacted by rising rates2026 Price Targets & Verified Stock Trade Ideas - baoquankhu1.vn

Market Recap: What are the risks of holding Processa Pharmaceuticals IncMarket Activity Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn

Processa Pharmaceuticals Inc Stock (PCSA) Financials Data

Revenue

Net Income

Cash Flow

EPS

Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading

Similar to PCSA